Facebook-f Tiktok Instagram Youtube Whatsapp Linkedin
Facebook-f Tiktok Instagram Youtube Whatsapp Linkedin
All Medical Experts

Doctor Profile

Oncology Center

Dr. Jian Hou

Hematology

Professor · Chief Physician · Doctoral Supervisor · MD

Dr. Hou is director of the Department of Hematology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; member of International Myeloma Working Group (IMWG); standing committee member and chair of the Plasma Cell Disorders Group, Hematology Branch, Chinese Medical Association; standing committee member of the Hematologic Malignancies Translational Medicine Committee, Chinese Anti-Cancer Association; standing committee member and vice chair of the Hematology Branch and Myeloma Committee, Chinese Medical Doctor Association; vice chair of the Drug Clinical Research Committee, China Association for the Promotion of Medical Innovation; chair-elect of the Hematologic Rehabilitation Committee, Chinese Association of Rehabilitation Medicine; standing committee member of the Anti-Lymphoma Alliance, Chinese Society of Clinical Oncology (CSCO); vice chair of the Anti-Leukemia Alliance, Chinese Society of Clinical Oncology (CSCO); standing committee member of the Experimental Hematology Branch, Chinese Society of Pathophysiology; standing committee member of the Hematology Immunology Branch, Chinese Society of Immunology; chair of the 10th Hematology Branch, Shanghai Medical Association; chair of the Hematology Immunology Committee, Shanghai Immunology Society.

Hematologic Expert

Plasma Cell Disorders

Multiple Myeloma

Hematologic Cancers

30+ yrs

Experience

50+

SCI Papers

30+

International & Domestic Guidelines

Expertise

Dr. Hou specializes in the diagnosis and personalized treatment of leukemia, lymphoma, and myeloma, excelling in targeted therapy, cellular immunotherapy, and hematopoietic stem cell transplantation for hematologic malignancies. Dr. Hou has achieved internationally advanced levels in managing plasma cell diseases, particularly multiple myeloma. Dr. Hou implements dual CAR-T therapy (CD19 and BCMA), achieving significant improvements in complex cases. Dr. Hou also specializes in autologous and allogeneic hematopoietic stem cell transplantation, combining precision targeting and immunotherapy to markedly enhance treatment efficacy and patient survival.

Professional Background

Dr. Hou is a leading expert in hematology with over 30 years of experience focusing on plasma cell disorders, especially multiple myeloma. He served as the principal investigator for two of the three myeloma-targeted drugs approved in China. As a key member of global clinical trials, his research contributed critically to the US and EU approvals of the anti-myeloma drugs Pomalidomide and Ixazomib. He has also participated in developing international guidelines and delivered keynote speeches at the International Myeloma Conference, earning him the title “Mr. Myeloma of China.” Dr. Hou has published over 50 findings in top journals including Lancet Oncology, Nature Communications, Blood, and JCO. He pioneered BCMA CAR-T therapy for relapsed/refractory multiple myeloma.

Awards & Honors

  • Received recognition from the International Myeloma Foundation (IMF)
  • Completed over 30 international and domestic multi-center clinical research projects
  • 2 First Prizes of Provincial/Municipal Science and Technology Progress Award
  • 3 Second Prizes of Provincial/Municipal Science, Technology and Medical Achievements Award
  • Recipient of Shanghai Health System Silver Snake Award
  • Shanghai Cross-Century Outstanding Discipline Leader
  • Shanghai Science and Technology Rising Star
  • Shanghai Shuguang Scholar
  • Shanghai Science and Technology Leading Talent
  • Shanghai Excellent Discipline Leader
  • Recipient of the Wu Jieping Medical Research Award

Recent Key Publications:

  1. Pu J , Liu T , Wang X ,et al.Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives[J].Experimental Hematology & Oncology, 2024, 13(1):19.DOI:10.1186/s40164-024-00507-5.
  2. Wang Q , Shi Q , Wang J H J .Integrating plasma proteomes with genome-wide association data for causal protein identification in multiple myeloma[J].bmc medicine, 2023, 21(1).DOI:10.1186/s12916-023-03086-0.
  3. Chen M , Jiang J , Hou J .Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications[J].biomarker research, 2023, 11(1).DOI:10.1186/s40364-023-00502-8.
  4. Du J , Yang Y C , An Z J ,et al.Advances in spatial transcriptomics and related data analysis strategies[J].Journal of Translational Medicine, 2023, 21(1):21.DOI:10.1186/s12967-023-04150-2.
  5. Li J , Ni B , Yu X ,et al.Metabolic kinetic modeling of [C-11]methionine based on total-body PET in multiple myeloma[J].European Journal of Nuclear Medicine and Molecular Imaging, 2023.DOI:10.1007/s00259-023-06219-y.
  6. Sun Y , Hou J , Li X ,et al.Prognostic value of left atrial longitudinal strain by cardiac MRI feature tracking in atrial fibrillation patients with mitral valve disease[J].Clinical radiology, 2022, 77(8):e643-e651.DOI:10.1016/j.crad.2022.05.008.
  7. Fang Y , Hou J .Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma[J].Military Medical Research, 2021, 8(1).DOI:10.1186/s40779-021-00302-x.
  8. Wan Y , Cheng Y , Liu Y ,et al.Screening and identification of a novel FHL2 mutation by whole exome sequencing in twins with familial Waldenstrm macroglobulinemia[J].Cancer, 2021.DOI:10.1002/cncr.33454.
  9. Zhang M , Gao F , Peng L ,et al.Distinct clinical features and prognostic factors of hepatitis C virus-associated non-Hodgkin’s lymphoma: a systematic review and meta-analysis.[J].Springer Science and Business Media LLC, 2021(1).DOI:10.1186/S12935-021-02230-1.
  10. Li R , Zheng C , Wang Q ,et al.Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma[J].Haematologica, 2020:haematol.2019.236836.DOI:10.3324/haematol.2019.236836.
  11. Xiao F , Huang H , Hua Y ,et al.Efficacy and Safety of Lenalidomide, Rituximab Combined with Second-Line Chemotherapy (R2-chemo) in Patients with Relapsed/Refractory Diffuse Large-B Cell Lymphoma[J].Blood, 2020, 136(Sup1).DOI:10.1182/blood-2020-141152.
  12. Fang Y , Xiao F , Fang J ,et al.A Rare Aggressive Case of Follicular Dendritic Cell Sarcoma[J].Blood, 2020, 136:18-18.DOI:10.1182/blood-2020-142259.
  13. Horvath N , Spencer A , Kenealy M ,et al.Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study[J].Leukemia & Lymphoma, 2019:1-12.DOI:10.1080/10428194.2019.1579322.
  14. Ma L , Xu S , Qu J ,et al.Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study.[J].Hematol Oncol, 2019(1).DOI:10.1002/hon.2548.
  15. Lu J , Lu J , Chen W ,et al.drug design, development and therapy dovepress more frequent igd and reduced cd200 expression in chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis[J]. 2019.DOI:10.2147/dddt.s100062.
  16. Zhang G , Hou J , Wang Y ,et al.Vulnerability analysis and optimization of power communication network[J]. DOI:10.1145/3338840.3355643.
  17. Wang W , Wang Y , Hou J ,et al.Flooding Influences Waterbird Abundance at Poyang Lake, China[J].Waterbirds, 2019, 42(1):30-38.DOI:10.1675/063.042.0104.
  18. Xu J , Chen L J , Yang S S ,et al.PNAS Plus: Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma[J].Proceedings of the National Academy of Sciences of the United States of America, 2019, 116(19).DOI:10.1073/pnas.1819745116.
  19. Zhou L , Jiang H , Du J ,et al.USP15 inhibits multiple myeloma cell apoptosis through activating a feedback loop with the transcription factor NF-κ[J].Experimental & Molecular Medicine, 2018(11).DOI:10.1038/S12276-018-0180-4.
  20. Tan D , Lee J H , Chen W ,et al.Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myelomworkshop[J].Leukemia & Lymphoma, 2018:1-13.DOI:10.1080/10428194.2018.1427858.
Book Appointment

Contact Us

We would love to speak with you.
Feel free to reach out using the below details.

Find us Here

  • +1 8324667523
  • services@chinahealthtrip.com

Fill out the form below!

Oncology Center

Doctor Profile

Dr. Jian Hou

Hematology

Professor · Chief Physician · Doctoral Supervisor · MD

Hematologic Expert

Plasma Cell Disorders

Multiple Myeloma

Hematologic Cancers

 

Dr. Hou is director of the Department of Hematology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; member of International Myeloma Working Group (IMWG); standing committee member and chair of the Plasma Cell Disorders Group, Hematology Branch, Chinese Medical Association; standing committee member of the Hematologic Malignancies Translational Medicine Committee, Chinese Anti-Cancer Association; standing committee member and vice chair of the Hematology Branch and Myeloma Committee, Chinese Medical Doctor Association; vice chair of the Drug Clinical Research Committee, China Association for the Promotion of Medical Innovation; chair-elect of the Hematologic Rehabilitation Committee, Chinese Association of Rehabilitation Medicine; standing committee member of the Anti-Lymphoma Alliance, Chinese Society of Clinical Oncology (CSCO); vice chair of the Anti-Leukemia Alliance, Chinese Society of Clinical Oncology (CSCO); standing committee member of the Experimental Hematology Branch, Chinese Society of Pathophysiology; standing committee member of the Hematology Immunology Branch, Chinese Society of Immunology; chair of the 10th Hematology Branch, Shanghai Medical Association; chair of the Hematology Immunology Committee, Shanghai Immunology Society.

Experience

0 +yrs
0 +

SCI Papers

0 +

International & Domestic Guidelines

Expertise

Dr. Hou specializes in the diagnosis and personalized treatment of leukemia, lymphoma, and myeloma, excelling in targeted therapy, cellular immunotherapy, and hematopoietic stem cell transplantation for hematologic malignancies. Dr. Hou has achieved internationally advanced levels in managing plasma cell diseases, particularly multiple myeloma. Dr. Hou implements dual CAR-T therapy (CD19 and BCMA), achieving significant improvements in complex cases. Dr. Hou also specializes in autologous and allogeneic hematopoietic stem cell transplantation, combining precision targeting and immunotherapy to markedly enhance treatment efficacy and patient survival.

Professional Background

Dr. Hou is a leading expert in hematology with over 30 years of experience focusing on plasma cell disorders, especially multiple myeloma. He served as the principal investigator for two of the three myeloma-targeted drugs approved in China. As a key member of global clinical trials, his research contributed critically to the US and EU approvals of the anti-myeloma drugs Pomalidomide and Ixazomib. He has also participated in developing international guidelines and delivered keynote speeches at the International Myeloma Conference, earning him the title “Mr. Myeloma of China.” Dr. Hou has published over 50 findings in top journals including Lancet Oncology, Nature Communications, Blood, and JCO. He pioneered BCMA CAR-T therapy for relapsed/refractory multiple myeloma.

 

Awards & Honors

Received recognition from the International Myeloma Foundation (IMF)

Completed over 30 international and domestic multi-center clinical research projects

2 First Prizes of Provincial/Municipal Science and Technology Progress Award

3 Second Prizes of Provincial/Municipal Science, Technology and Medical Achievements Award

Recipient of Shanghai Health System Silver Snake Award

Shanghai Cross-Century Outstanding Discipline Leader

Shanghai Science and Technology Rising Star

Shanghai Shuguang Scholar

Shanghai Science and Technology Leading Talent

Shanghai Excellent Discipline Leader

Recipient of the Wu Jieping Medical Research Award

Professional Background

  1. Pu J , Liu T , Wang X ,et al.Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives[J].Experimental Hematology & Oncology, 2024, 13(1):19.DOI:10.1186/s40164-024-00507-5.
  2. Wang Q , Shi Q , Wang J H J .Integrating plasma proteomes with genome-wide association data for causal protein identification in multiple myeloma[J].bmc medicine, 2023, 21(1).DOI:10.1186/s12916-023-03086-0.
  3. Chen M , Jiang J , Hou J .Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications[J].biomarker research, 2023, 11(1).DOI:10.1186/s40364-023-00502-8.
  4. Du J , Yang Y C , An Z J ,et al.Advances in spatial transcriptomics and related data analysis strategies[J].Journal of Translational Medicine, 2023, 21(1):21.DOI:10.1186/s12967-023-04150-2.
  5. Li J , Ni B , Yu X ,et al.Metabolic kinetic modeling of [C-11]methionine based on total-body PET in multiple myeloma[J].European Journal of Nuclear Medicine and Molecular Imaging, 2023.DOI:10.1007/s00259-023-06219-y.
  6. Sun Y , Hou J , Li X ,et al.Prognostic value of left atrial longitudinal strain by cardiac MRI feature tracking in atrial fibrillation patients with mitral valve disease[J].Clinical radiology, 2022, 77(8):e643-e651.DOI:10.1016/j.crad.2022.05.008.
  7. Fang Y , Hou J .Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma[J].Military Medical Research, 2021, 8(1).DOI:10.1186/s40779-021-00302-x.
  8. Wan Y , Cheng Y , Liu Y ,et al.Screening and identification of a novel FHL2 mutation by whole exome sequencing in twins with familial Waldenstrm macroglobulinemia[J].Cancer, 2021.DOI:10.1002/cncr.33454.
  9. Zhang M , Gao F , Peng L ,et al.Distinct clinical features and prognostic factors of hepatitis C virus-associated non-Hodgkin’s lymphoma: a systematic review and meta-analysis.[J].Springer Science and Business Media LLC, 2021(1).DOI:10.1186/S12935-021-02230-1.
  10. Li R , Zheng C , Wang Q ,et al.Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma[J].Haematologica, 2020:haematol.2019.236836.DOI:10.3324/haematol.2019.236836.
  11. Xiao F , Huang H , Hua Y ,et al.Efficacy and Safety of Lenalidomide, Rituximab Combined with Second-Line Chemotherapy (R2-chemo) in Patients with Relapsed/Refractory Diffuse Large-B Cell Lymphoma[J].Blood, 2020, 136(Sup1).DOI:10.1182/blood-2020-141152.
  12. Fang Y , Xiao F , Fang J ,et al.A Rare Aggressive Case of Follicular Dendritic Cell Sarcoma[J].Blood, 2020, 136:18-18.DOI:10.1182/blood-2020-142259.
  13. Horvath N , Spencer A , Kenealy M ,et al.Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study[J].Leukemia & Lymphoma, 2019:1-12.DOI:10.1080/10428194.2019.1579322.
  14. Ma L , Xu S , Qu J ,et al.Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study.[J].Hematol Oncol, 2019(1).DOI:10.1002/hon.2548.
  15. Lu J , Lu J , Chen W ,et al.drug design, development and therapy dovepress more frequent igd and reduced cd200 expression in chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis[J]. 2019.DOI:10.2147/dddt.s100062.
  16. Zhang G , Hou J , Wang Y ,et al.Vulnerability analysis and optimization of power communication network[J]. DOI:10.1145/3338840.3355643.
  17. Wang W , Wang Y , Hou J ,et al.Flooding Influences Waterbird Abundance at Poyang Lake, China[J].Waterbirds, 2019, 42(1):30-38.DOI:10.1675/063.042.0104.
  18. Xu J , Chen L J , Yang S S ,et al.PNAS Plus: Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma[J].Proceedings of the National Academy of Sciences of the United States of America, 2019, 116(19).DOI:10.1073/pnas.1819745116.
  19. Zhou L , Jiang H , Du J ,et al.USP15 inhibits multiple myeloma cell apoptosis through activating a feedback loop with the transcription factor NF-κ[J].Experimental & Molecular Medicine, 2018(11).DOI:10.1038/S12276-018-0180-4.
  20. Tan D , Lee J H , Chen W ,et al.Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myelomworkshop[J].Leukemia & Lymphoma, 2018:1-13.DOI:10.1080/10428194.2018.1427858.

Contact Us

We would love to speak with you.
Feel free to reach out using the below details.

Find us Here

  • +1 8324667523
  • chinahealthtripen@gmail.com

Fill out the form below!

WhatsApp

Book Your Appointment